LONGEVA.

SS-31: adverse events and evidence limits

A 24-week subcutaneous elamipretide trial in genetically confirmed primary mitochondrial myopathy reported injection-site redness, itching, pain and swelling. Elamipretide is also called SS-31. [1,2]

Serious events occurred in both arms and were assessed as unrelated to treatment. This does not establish catalog-material or other-route safety. [1,2]

What the studies reported

EffectModel or participantsHow often or as describedSource
Injection-site rednessPatients with genetically confirmed primary mitochondrial myopathy, subcutaneous elamipretide, 24 weeksReported; no percentage given in the abstracts[1,2]
Injection-site itchingThe same patientsReported; no frequency given[1,2]
Injection-site painThe same patientsReported; no frequency given[1,2]
Injection-site swellingThe same patientsReported; no frequency given[1,2]
Serious eventsThe same patientsOccurred in both arms and were assessed as unrelated to treatment[1,2]

References

  1. Amel Karaa et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial https://doi.org/10.1212/WNL.0000000000207402.
  2. W Reid Thompson et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism https://doi.org/10.1038/s41436-020-01006-8.